Analysts Set Expectations for Perspective Therapeutics Q1 Earnings

Key Points

• Brookline Capital Markets expects Perspective Therapeutics to post a Q1 2027 loss of $0.26 per share, with projected losses of $0.27 in Q2, $0.30 in Q3 and $1.14 for full-year 2027.
• The company’s latest quarterly loss of $0.22 per share beat analysts’ $0.25 loss estimate by $0.03, although revenue of $0.08 million fell short of the $0.09 million consensus.
• Analyst sentiment remains positive, with eight Buy ratings, a consensus “Buy” rating and a $12.38 price target; the stock recently traded at $3.26, while institutional investors and hedge funds own 54.66% of shares.

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX - Free Report) - Equities research analysts at Brookline Capital Markets issued their Q1 2027 earnings per share estimates for shares of Perspective Therapeutics in a report released on Tuesday, August 11th. Brookline Capital Markets analyst K. Dolliver anticipates that the company will earn ($0.26) per share for the quarter. The consensus estimate for Perspective Therapeutics' current full-year earnings is ($1.10) per share. Brookline Capital Markets also issued estimates for Perspective Therapeutics' Q2 2027 earnings at ($0.27) EPS, Q3 2027 earnings at ($0.30) EPS and FY2027 earnings at ($1.14) EPS.

Perspective Therapeutics (NYSEAMERICAN:CATX - Get Free Report) last issued its earnings results on Monday, August 10th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.03. The firm had revenue of $0.08 million for the quarter, compared to analyst estimates of $0.09 million. Perspective Therapeutics had a negative return on equity of 44.22% and a negative net margin of 28,467.97%.

Several other analysts also recently weighed in on the stock. Wedbush reiterated an "outperform" rating and issued a $11.00 price objective on shares of Perspective Therapeutics in a research report on Tuesday, May 5th. BTIG Research restated a "buy" rating on shares of Perspective Therapeutics in a research report on Friday, July 24th. Finally, Piper Sandler dropped their price target on shares of Perspective Therapeutics from $16.00 to $14.00 and set an "overweight" rating on the stock in a research note on Tuesday. Eight analysts have rated the stock with a Buy rating, According to MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $12.38.

Perspective Therapeutics Stock Performance

Perspective Therapeutics stock opened at $3.26 on Thursday. The company has a 50-day simple moving average of $3.08 and a 200-day simple moving average of $3.94. Perspective Therapeutics has a one year low of $1.96 and a one year high of $6.16.

Institutional Trading of Perspective Therapeutics

Institutional investors have recently made changes to their positions in the stock. Aigen Investment Management LP acquired a new position in shares of Perspective Therapeutics during the fourth quarter valued at approximately $28,000. Russell Investments Group Ltd. lifted its position in Perspective Therapeutics by 184.1% in the third quarter. Russell Investments Group Ltd. now owns 8,449 shares of the company's stock worth $29,000 after purchasing an additional 5,475 shares during the period. nVerses Capital LLC acquired a new stake in Perspective Therapeutics in the fourth quarter worth approximately $31,000. AXQ Capital LP boosted its stake in Perspective Therapeutics by 24.2% during the 4th quarter. AXQ Capital LP now owns 12,749 shares of the company's stock valued at $35,000 after purchasing an additional 2,481 shares in the last quarter. Finally, Engineers Gate Manager LP bought a new position in Perspective Therapeutics during the 4th quarter valued at $35,000. 54.66% of the stock is owned by institutional investors and hedge funds.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source